title: Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?
abstract: An excess of reactive carbonyl compounds (carbonyl stress) and their reaction products, advanced glycation endproducts (AGEs), are thought to play a decisive role in the pathogenesis of neurodegenerative disorders and Parkinson's disease (PD) in particular. Accumulation of AGEs in various intracellular pathological hallmarks of PD, such as Lewy bodies, densely crosslinked intracellular protein deposits formed from neurofilament components and alpha-synuclein, have already been described in patients in advanced stages of the disease. There is, however, no indication of the involvement of AGE-induced crosslinking of alpha-synuclein in very early stages of the disease. In this study, we observed that AGEs and alpha-synuclein are similarly distributed in very early Lewy bodies in the human brain in cases with incidental Lewy body disease. These cases might be viewed as pre-Parkinson patients, i.e. patients who came for autopsy before the possible development of clinical signs of PD. AGEs are both markers of transition metal induced oxidative stress as well as, inducers of protein crosslinking and free radical formation by chemical and cellular processes. Thus, it is likely that AGE promoted formation of Lewy bodies reflects very early causative changes rather than late epiphenomenons of PD.
authors.affiliation: Neuroimmunological Cell Biology Group, Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Leipzig, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Münch
authors.forename: H J
authors.initials: HJ
authors.lastname: Lüth
authors.forename: A
authors.initials: A
authors.lastname: Wong
authors.forename: T
authors.initials: T
authors.lastname: Arendt
authors.forename: E
authors.initials: E
authors.lastname: Hirsch
authors.forename: R
authors.initials: R
authors.lastname: Ravid
authors.forename: P
authors.initials: P
authors.lastname: Riederer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000906:Antibodies; D003432:Cross-Linking Reagents / Q000378:metabolism*; D005260:Female; D017127:Glycation End Products, Advanced / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D016631:Lewy Bodies / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D008297:Male; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology*; D011817:Rabbits; D012995:Solubility; D051843:Synucleins; D051844:alpha-Synuclein
chemical_list: D000906:Antibodies; D003432:Cross-Linking Reagents; D017127:Glycation End Products, Advanced; D009419:Nerve Tissue Proteins; C497604:SNCA protein, human; D051843:Synucleins; D051844:alpha-Synuclein